Cambium Bio Limited has released a press release.
Sygenus shows longer lasting effect on pain than morphine
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Cambium Bio
- Regeneus receives R&D tax incentive refund of $2.6m
- Appendix 4E Revised
- US patent allowed for Sygenus for acne
- RGS to receive milestone payment for successful Phase I
- Japanese Patent Office to grant key patent for Progenza
Later from Cambium Bio
- CEO Presentation to 2017 Annual General Meeting
- Regeneus Announces Successful Results in Acne Study
- Japanese Patent Office to grant patent for cancer vaccine
- European Medicines Agency grants Progenza ATMP status
- Update on licensing Progenza in Japan
Follow Cambium Bio into a list and get an email when it puts out news.
Follow Cambium Bio